aTYR PHARMA (ATYR) Net Cash Flow Growth (3y) (2017 - 2026)
Powered by 
Analysis
aTYR PHARMA (ATYR) Net Cash Flow Growth (3y) (2017 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 208.48 Bn | 194.49 Bn | 7.24 Bn | -10.13% |
| 2 | Gilead Sciences | 186.29 Bn | 183.02 Bn | 6.22 Bn | -98.96% |
| 3 | Vertex Pharmaceuticals | 128.79 Bn | 120.93 Bn | 2.84 Bn | -8.34% |
| 4 | Regeneron Pharmaceuticals | 80.66 Bn | 72.67 Bn | 3.93 Bn | 36.60% |
| 5 | Moderna | 61.46 Bn | 56.32 Bn | 52.00 Mn | -35.85% |
| 6 | Argenx Se | 61.28 Bn | 56.10 Bn | 1.37 Bn | - |
| 7 | Alnylam Pharmaceuticals | 32.04 Bn | 28.73 Bn | 992.69 Mn | 67.39% |
| 8 | Biogen | 31.84 Bn | 30.56 Bn | 1.96 Bn | -96.44% |
| 9 | Roivant Sciences | 28.74 Bn | 29.43 Bn | 1.16 Mn | - |
| 10 | aTYR PHARMA | 35.31 Mn | -22.30 Mn | - | 39.54% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 39.54% |
| Mar 31, 2026 | -28.23% |
| Dec 31, 2025 | 36.66% |
| Sep 30, 2025 | -44.02% |
| Jun 30, 2025 | 101.48% |
| Mar 31, 2025 | -30.11% |
| Dec 31, 2024 | 81.26% |
| Sep 30, 2024 | -56.67% |
| Jun 30, 2024 | 68.63% |
| Mar 31, 2024 | -54.21% |
| Dec 31, 2023 | 133.11% |
| Sep 30, 2023 | 10.52% |
| Jun 30, 2023 | 22.96% |
| Mar 31, 2023 | -29.20% |
| Dec 31, 2022 | 2.86% |
| Sep 30, 2022 | 58.95% |
| Jun 30, 2022 | -16.65% |
| Mar 31, 2022 | 37.49% |
| Dec 31, 2021 | -88.40% |
| Sep 30, 2021 | 67.37% |